Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Minnesota for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Minnesota only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Minnesota (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Jason Raasch (NPI 1811095854)

Field	Value
Entity Type	Individual
Organization	Jason Raasch
Address	15700 37th Ave N
City	Plymouth
State	MN
ZIP	55446
Taxonomy	Allergy & Immunology Physician
NPI Enumerated	September 21, 2006

Payer Source	Total Paid
Medicare	$2.1M
Medicaid	$0

Key Findings

This provider’s Medicare revenue footprint is concentrated in infused specialty biologics and immunologic therapies: the three highest-revenue codes are J2350 ($938.4K, 44.8%), J1569 ($459.4K, 21.9%), and J1568 ($355.9K, 17.0%), and these top 3 codes together account for 83.7% of total Medicare revenue. The code mix (ocrelizumab and multiple formulations of immune globulin) and sizeable claim volumes for injection/infusion products indicate an operational model built around high-throughput infusion services rather than predominantly office-based care.

Lifetime Medicare revenue is $2.1M while there is no Medicaid billing on file, so this provider functions effectively as a single-payer (Medicare) reporter in the available data. The lack of Medicaid activity limits any analysis of in-state Medicaid competitiveness or dual-payer strategy.

Competitive standing for immune globulin is strong on a national scale: J1569 ranks #25 of 542 providers nationally (96th percentile) and J1568 ranks #25 of 381 providers nationally (93th percentile), both labeled in the source as "typical, unremarkable volume" despite their high percentiles. J2350 ranks #24 of 105 providers nationally (78th percentile), placing the provider above median national volume for that therapy but not at the very top of national reporters.

Operational throughput is reinforced by high national percentile positions on infusion administration codes: 96365 (401 claims, $18.4K revenue) ranks #573 of 8873 providers nationally (94th percentile) and 96366 (483 claims, $7.2K revenue) ranks #165 of 2976 providers nationally (94th percentile). These high percentile ranks for infusion administration codes are consistent with a practice that bills mainly for in-office IV drug administration and subsequent infusions.

Clinical visit volume is minimal relative to infusion activity, supporting the inference of an infusion-centric practice rather than a primary ambulatory clinic. For example, 99213 shows 36 claims ($2.2K revenue, 0.1% of Medicare revenue) and 99214 shows 24 claims ($2.1K revenue, 0.1% of Medicare revenue), indicating limited evaluation-and-management billing.

The provider’s code-level mix includes other specialty injectables and supportive codes (J2323, J0897, J1720) and some chemotherapy-related administration codes (96413, 96415) at low revenue shares, which suggests occasional use of related specialty therapies but not a broad oncology service line. These codes generally appear with small revenue shares (each under 1% of total Medicare revenue) and carry the source label "typical, unremarkable volume," implying these are secondary to the provider’s immunology/infusion business.

There are no source labels in this dataset identifying extreme outlier behavior; most reported codes are described as "typical, unremarkable volume." Even where the provider ranks highly (e.g., J1569 and J1568), the dataset’s plain-English labels do not flag anomalous patterns, so the observed high-volume immune globulin activity should be interpreted as a sustained clinical/service focus rather than a statistically flagged exception.

The provider has an established Medicare enrollment history (NPI enumerated on 2006-09-21, ~20 years ago), which supports interpretation of the observed revenue and code patterns as stable, long-standing practice behavior rather than a short-lived reporting artifact. The absence of Medicaid billing on file means any competitive conclusions should be limited to the Medicare market and national peer comparisons shown in the data.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

17 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J2350	Injection, ocrelizumab, 1 mg	20,400	$50	$938.4K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	12,760	$40	$459.4K
J1568	Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg	11,480	$30	$355.9K
J2323	Injection, natalizumab, 1 mg	14,700	$20	$264.6K
J0897	Injection, denosumab, 1 mg	1,380	$20	$26.2K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	400	$50	$18.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	130	$90	$11.2K
96366	The provider administers an intravenous infusion or infusions of a medication for an additional hour or subsequent hours after the first hour to prevent, treat, or diagnose a condition or disease.	480	$20	$7.2K
96375	Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the…	260	$10	$2.8K
99213	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the…	40	$60	$2.2K

Showing 1–10 of 17

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 17 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Minnesota Distribution

Jason Raasch — 5 of 17 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Minnesota

Full comparison — all codes billed, vs. state median

17 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J2350	2	10	19,500	$50	$1M
J2323	1	10	14,700	$20	$265.5K
J1568	1	10	3,560	$30	$141.7K
J1569	1	10	3,220	$30	$137.2K
J0897	59	90	1,770	$20	$50.8K
96413	75	230	70	$100	$11.5K
99214	8,342	10,100	70	$80	$8.1K
99213	5,430	9,120	50	$50	$4K
96365	7	260	30	$50	$3.2K
96375	39	140	120	$10	$2.2K

Showing 1–10 of 17

Related Providers

Other providers that share a Tax Identification Number (TIN) with Jason Raasch, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Emma Singh	PA	Family Medicine Physician	$1.5M	$0
Christopher Cronsell	WI	Physical Medicine & Rehabilitation Physician	$1.4M	$0
Andrea Gillon	MI	Family Nurse Practitioner	$1.4M	$0
Jonathan Calkwood	MN	Neurology Physician	$1.3M	$0
Heli Hunter	MN	Nurse Practitioner	$1.2M	$0
Kimberly Agim	MI	Nurse Practitioner	$1.1M	$0
Andrea Enters	WI	Gerontology Nurse Practitioner	$92.9K	$0
Kathleen Steensma	MN	Family Nurse Practitioner	$53.7K	$0
Anna Cluskey	WI	Medical Physician Assistant	$19.3K	$0
Bhupendra Khatri	WI	Neurology Physician	$17.1K	$0

Nearby Providers

Other providers in the same ZIP code as Jason Raasch, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
David Strothman	MN	Orthopaedic Surgery Physician	$93.2K	$0
Steven Sabers	MN	Pain Medicine (Physical Medicine & Rehabilitation) Physician	$92.7K	$0
Steven Stulc	MN	Pain Medicine (Physical Medicine & Rehabilitation) Physician	$73.9K	$0
Erik Ekstrom	MN	Physical Medicine & Rehabilitation Physician	$69.5K	$0
Michael Freehill	MN	Orthopaedic Surgery Physician	$69.5K	$0
David Spight	MN	Pain Medicine (Physical Medicine & Rehabilitation) Physician	$64.7K	$0
Mancel Mitchell	MN	Family Medicine Physician	$53.8K	$0
Thomas Kaminsky	MN	Gastroenterology Physician	$52.2K	$1.2K
Erica Roberson	MN	Gastroenterology Physician	$52.4K	$0
Jose Vega Peralta	MN	Gastroenterology Physician	$37.7K	$0

Jason Raasch — Billing Profile & Reimbursement Data

Sign up for Jason Raasch — Billing Profile & Reimbursement Data policy alerts

Jason Raasch — Billing Profile & Reimbursement Data

Sign up for Jason Raasch — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References